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Prevalence of amebiasis in inflammatory 
bowel disease in University Clinical Hospital 
Mostar
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Danijel Pravdić1 and Nikica Šutalo3
Abstract 
Aim: To explore the prevalence of amebiasis in inflammatory bowel disease (IBD), Crohn’s disease and ulcerative 
colitis, in patients in Clinical hospital Mostar (Bosnia and Herzegovina, region of Herzegovina).
Methods: In this study, Entamoeba histolytica/dispar prevalence was investigated in fresh faeces by native micros-
copy and immunochromatographic rapid assay “RIDA®QUICK Entamoeba test”, in 119 cases of new found IBD patients, 
84 of ulcerative colitis and 35 of Crohn’s disease and in control group who had also 119 patients who didn’t have any 
gastrointestinal complaints. IBD diagnosis was established by standard diagnostic procedures (anamnesis, clinical 
manifestations, laboratory, endoscopy and biopsy).
Results: Entamoeba histolytica/dispar were found in 19 (16.0 %) of a total of 119 cases, 12 (14.3 %) of the 84 patients 
with ulcerative colitis and 7 (20.0 %) of the 35 patients with Crohn’s disease. As for the 119 patients in the control 
group who had not any gastrointestinal complaints, 2 (1.7 %) patients were found to have E. histolytica/dispar in their 
faeces. Amoeba prevalence in the patient group was determined to be significantly higher in group with Crohn’s 
disease, ulcerative colitis and IBD total than in the control group (p < 0.001).
Conclusion: Ameba infections in patients with Crohn’s disease and ulcerative colitis, have a greater prevalence com-
pared to the normal population.
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Background
Amebiasis affects around 500 million people in the world 
today (Andersen 2000). It is more prevalent in develop-
ing countries (Lau et  al. 2013; Verma et  al. 2012). The 
prevalence of parasite infections and amebiasis is very 
high in Mediterranean region (Abdulsalam et  al. 2013; 
Ozçelik et al. 2012; El Guamri et al. 2011). Symptoms of 
amebiasis can overlap with symptoms of the inflamma-
tory bowel disease (IBD). It can leads to difficulty in diag-
nosis and treatment in IBD (Hansen and Lund 1998). In 
that case the diagnosis and management of inflammatory 
bowel disease can be challenging as certain infections 
can mimic IBD and lead to a misdiagnosis. Because of 
the increasing use of corticosteroids, immunosuppres-
sive drugs and biological agents the risk of opportunis-
tic infection including amebiasis are also higher in IBD 
patients. The role of the physician lies not only in the 
diagnosis and management of IBD but also in the ability 
to prevent, recognize and treat infections.
Entamoeba histolytica and Entamoeba dispar are intra-
luminal parasites. Entamoeba histolytica is invasive spe-
cies and cause symptomatic disease characterized with 
abdominal pain, cramps, blood diarrhea. Entamoeba 
dispar is non-invasive species which is useful as a study 
model for E. histolytica because both species have a lot 
of identical gens regions and similar immunogenic effect 
(Willhoeft et  al. 1999; Bruchhaus et  al. 1996; Jacobs 
Open Access
*Correspondence:  emil.babic@yahoo.com 
1 Department of Gastroenterology and Hepatology, University of Mostar 
Clinical Hospital, Bijeli Brijeg bb, 88000 Mostar, Bosnia and Herzegovina
Full list of author information is available at the end of the article
Page 2 of 4Babić et al. SpringerPlus  (2016) 5:1586 
et al. 1998). IBD is a chronic inflammatory condition of 
the intestines caused by inadequate mucosal immune 
response to antigenic components. It is manifested in 
two major subtypes: Crohn disease and ulcerative colitis. 
A consensus hypothesis is that in genetically predisposed 
individuals, a combination of factors including luminal 
flora and host characteristics result in a chronic state of 
dysregulated mucosal immune function. This results in 
an “inappropriate response” to normal microbial flora 
within the intestine, with or without some component of 
autoimmunity (Friedman and Blumberg 2008).
Amebiasis can exacerbate symptoms of IBD and has 
unfavorable influence on course of disease and therapy. 
Inadequate mucosal immune response on the intralumi-
nal antigenic components is essential in IBD pathogen-
esis (Kaser et al. 2010).
In this study, the prevalence of Entamoeba histolytica/
dispar in the patients hospitalized in Clinical hospital 
Mostar in Herzegovina region with predominantly Medi-
terranean climate, diagnosed with either Crohn’s disease 
or ulcerative colitis was investigated.
Methods
IBD were diagnosed in 119 patients by clinical presen-
tation, laboratory and serological, endoscopic and his-
topathologic examinations at Department of internal 
medicine, University clinical hospital Mostar between 
March 2009 and December 2011. All patients were 
treated in gastroenterology ambulance and clinic and 
IBD (Crohn disease and ulcerative colitis) were con-
firmed by standard procedure. There was 84 patients 
diagnosed as ulcerative colitis (70.6 %) and 35 as Crohn’s 
disease (29.4 %).
Also, 119 patients in the control group was formed by 
healthy individuals, without gastrointestinal complains 
and have regular medical examinations which include 
laboratory examinations and native microscopic exam 
of fresh feces samples. Therefore, control group was not 
matched in any way with IBD patients, except of course 
by age and gender (Tables 1, 2).
If native microscopy was found Entamoeba hystolitica/
dispar cysts or trophozoits, immunochromatographic 
rapid assay “RIDA®QUICK Entamoeba test” is used to 
confirm diagnosis. Native microscopy is performed by 
the optical microscope, enlargement factor 10× and 40×. 
Fresh faeces samples taken from people were examined 
immediately using the wet mount, Lugol’s iodine and 
physiological solution. χ2 test was applied to the groups 
(ulcerative colitis, Crohn’s disease and control) for a com-
parison of amoeba frequency among them.
Results
Entamoeba histolytica/dispar cysts and trophozoits were 
found in 19 (16 %) of the 119 IBD cases and in 2 cases of 
the control group (1.7 %) (Table 3). Frequency of E. histo-
lytica/dispar in patients with IBD was significantly higher 
than in control group (Chi square test, p < 0.001). When 
the groups of patients with IBD were compared with the 
control group separately, the frequency of E histolytica/
dispar in patients with ulcerative colitis and Crohn’s 
disease were also significantly higher than in the con-
trol group. E. histolytica/dispar were determined in 12 
(14.3 %) of the 84 patients with ulcerative colitis and in 7 
(20 %) patients with Crohn’s disease (Table 4).
Demographics results about comparison between IBD, 
amebiasis and control group are shown in Table 5.
There was not significant difference between male and 
female patients with IBD and amebiasis compared with 
the control group and it was not found that gender is risk 
Table 1 Age distribution of male patients and controls
* Student t test
Age (years) (X ± SD) Male patients Control t* p
<37 28.27 ± 5.05 29.87 ± 5.82 0.885 0.382
38–52 45.10 ± 4.16 47.00 ± 4.31 1.381 0.176
≥53 63.95 ± 8.22 62.11 ± 8.42 0.682 0.5
Table 2 Age distribution of female patients and controls
* Student t test
Age (years) (X ± SD) Female patients Control t* p
<37 27.62 ± 5.45 29.96 ± 5.23 1.483 0.145
38–52 46.44 ± 4.55 46.42 ± 3.74 0.022 0.983
≥53 66.32 ± 7.81 62.94 ± 7.39 1.347 0.187
Table 3 Prevalence of amebiasis in IBD and control group
χ2 = 13.37, p < 0.001
χ2 = Chi square test
Entamoeba histolytica/dispar N (%)
IBD Control group
Negative 100 (84.0) 117 (98.3)
Positive 19 (16.0) 2 (1.7)
Table 4 Prevalence of  amebiasis in  ulcerative colitis 
and Crohn’s disease
χ2 = 16.194, p < 0.001
UC ulcerative colitis, CD Crohn’s disease, χ2 = Chi square test
Entamoeba histolytica/dispar N (%)
UC CD Control group
Negative 72 (85.7) 28 (80.0) 117 (98.3)
Positive 12 (3.14) 7 (20.0) 2 (1.7)
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factor for amebiasis in IBD (Chi square test, p =  0.014 
and p = 0.021). E. histolytica/dispar cysts and trophozo-
its were found in 11 (18.0 %) of the 61 IBD cases in male 
and 8 (13.8 %) of the 58 IBD cases in female.
Comparing results with previous studies, our results 
show higher prevalence of amebiasis in CD (Table 6).
Discussion
Entamoeba histolytica/dispar were determined in 19 (16 %) 
of the 119 patients with IBD and it was significantly higher 
than in control group (1.7  %). E. histolytica/dispar were 
determined in 12 (14.3  %) of the 84 patients with ulcera-
tive colitis. Results from our study showed higher incidence 
than study of Prokopowicz et al. performed in Poland where 
prevalence of amebiasis in ulcerative colitis was five out of 
103 patients which accounts for 4.85 % (Prokopowicz et al. 
1994). Studies performed in Turkey were found higher prev-
alence of amebiasis up to 69 %. Bayramicli et al. were found 
the presence of amebiasis in 19 patients with diagnosis of 
ulcerative colitis and found amebiasis in 69 % oft he cases 
(Bayramicli et al. 1997). In a study they carried out by Suley-
manlar et al. found E. histolytica cysts and trophozoites in 22 
(54 %) oft he patients (Suleymanlar et al. 1996). Prevalence 
of amebiasis in ulcerative colitis seemed higher in countries 
with Mediterranean than continental climate. It is important 
to distinguish amebic colitis from IBD especially if amebiasis 
is present in the community or when the patient has visited 
an endemic area. Similarity in the symptomatology of these 
two diseases and the non-specific endoscopic findings can 
cause problem in diagnosis. Absence of amebic trophozoites 
and cysts in the stool in some cases of amoebic colitis can 
complicate diagnostic procedure because both amebic coli-
tis and IBD may present with similar symptoms like bloody 
diarrhoea, abdominal pain, haematochezia, anaemia and 
hypoproteinaemia. Continuous mucosal inflammation typi-
cal of ulcerative colitis can be seen also in amebic colitis. We 
were found E. histolytica/dispar in 20.0 % with Crohn’s dis-
ease patients and it is higher than results Ustun and Tozum 
in Turkey where E. histolytica/dispar were found in only 
13.3 and 10 % Crohn’s disease patients (Ustun et  al. 2003; 
Tözün 2002). The reason for higher incidence of amebiasis 
in our study could be the fact that amebiasis is not recog-
nized as public health problem in our country yet and the 
incidence of E. histolytica/dispar has been diminishing in 
Turkey in recent years. Not only amebic colitis and IBD may 
present with similar symptoms but endoscopic findings may 
be non-specific. For example, typical discrete flask-shaped 
ulcers of amebic colitis may also be seen in Crohn’s disease. 
It may be impossible to distinguish between the amebiasis 
and Crohn’s disease, since stool specimens, bowel biopsies, 
and serological studies may be negative for Entamoeba his-
tolytica, even in the presence of invasive amoebic colitis. 
Diagnosis in such cases can be established only by patholog-
ical examination of a surgically resected bowel. That’s why is 
important to consider anti-amebic therapy in endemic areas 
in cases of persistent IBD (Lysy et al. 1991). Adding to the 
difficulty in differentiating amebic colitis from IBD is the 
possibility of not seeing the amebic trophozoites and/or cyst 
in the stool in acute invasive colitis with diarrhoea, and the 
fact that serologic test are not readily available in all hospi-
tals, especially in our country. The pathological diagnosis of 
inflammatory bowel disease is often difficult because biopsy 
material may not contain pathognomonic features, making 
distinction between Crohn’s disease, ulcerative colitis and 
other forms of colitides a truly challenging exercise. The best 
way for reliant diagnosis is multidisciplinary approach when 
the full clinical history, endoscopic findings, radiology and 
relevant serology and microbiology are available (Woodman 
et al. 2015; Şimşek et al. 2016). This can be very important 
in patients with IBD because early anti-amebic therapy is 
essential and significantly influence on the course of dis-
ease. For example, in the study by Vinayak et al. trophozo-
ites of Entamoeba histolytica were seen in less than 40 % of 
stool microscopy in patients with invasive intestinal disease 
(Vinayak et al. 1993). It is difficult to differentiate between 
infection. In our study, we found CRP significantly high in 
Table 5 Prevalence of amebiasis by age group of patients 
with IBD and the control group
* Fisher test
Age (years) Broj (%)
Amebiasis IBD Control x2 p
≤37 9.676 0.002
Negative 32 (74.4) 40 (100.0)
Positive 11 (25.6) 0 (0.0)
Total 43 (100) 40 (100)
38–52 4.492 0.049*
Negative 32 (84.2) 41 (97.6)
Positive 6 (8.15) 1 (2.4)
Total 38 (100) 42 (100)
≥53 0.320 1.000*
Negative 36 (94.75) 36 (97.3)
Positive 2 (3.5) 1 (2.7)
Total 38 (100) 37 (100)
Table 6 Study prevalence comparison
χ2 = 11.55, p = 0.0031
UC ulcerative colitis, CD Crohn’s disease, χ2 = Chi square test
Study Number (%)
UC CD IBD
Babic et al. 12/84 (3.14) 7/35 (20) 19/100 (16)
Ustun et al. 13/130 (10) 1/30 (3.3) 14/160 (8.75)
Tozum et al. 284/854 (33) 24/234 (10) 308/1088 (28.3)
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patients with comorbidity of IBD and amebiasis. Other 
studies confirmed CRP as good parameter of inflammation 
and disease activity in IBD or amebiasis separately but we 
didn’t find data about correlation in CRP and both disease 
simultaneously (Kiss et  al. 2011; Ahmed et  al. 1992). This 
result indicates on necessity of future investigations about 
this. We did not found that amebiasis is gender correlated 
and prevalence was not significantly higher in males or 
females in IBD.
Conclusion
Results in our study indicate that differential diagnosis 
is extremely important for IBD and amebiasis patients, 
especially in region with high prevalence of amebiasis. 
It is essential to distinguish amebiasis colitis and IBD 
already on beginning of diagnostic algorithm (Ibrahim 
et al. 2005). Similarity in the symptoms of these two dis-
eases can complicate diagnostic procedure because both 
may present with similar symptoms. It is very important 
to considered amebic colitis in cases of exacerbation of 
symptoms in inflammatory bowel disease in region with 
high prevalence of amebiasis.
Our results confirmed possibility that decrease of pro-
tective factors in IBD (slim in bowels, loss of albumins, 
inappropriate nutrition) enables colonization by parasites, 
including E. histolytica/dispar (Vucelic 2002). There is 
hyperactivity of mucosal immune system to the intralu-
minal antigens in IBD where E. histolytica/dispar can par-
ticipate in initiation or maintenance of immune response.
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